XML 35 R4.htm IDEA: XBRL DOCUMENT v3.25.2
Consolidated Statements of Operations and Other Comprehensive Income (Loss) - USD ($)
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Income Statement [Abstract]    
Revenue [1] $ 3,052,532 $ 3,111,781
Cost of revenue (exclusive of amortization shown separately below) (1,805,673) (1,686,155) [2]
Gross profit 1,246,859 1,425,626
Other income    
Government support income 816,901 424,776
Operating expenses    
Selling, general and administrative expenses (8,883,917) (9,258,496)
Development and regulatory approval expenses (2,396,513) (1,673,806)
Depreciation and amortization (1,207,875) (1,201,274)
Impairment of long-lived assets (220,062)
Total operating expenses (12,708,367) (12,133,576)
Loss from operations (10,644,607) (10,283,174)
Other income (expense), net    
Interest expense (60,890) (167,140)
Realized foreign exchange loss (911) (1,178)
Fair value gain on revaluation of financial instrument 175,738
Interest income 101,522 84,822
Total other income, net [3] 39,721 92,242
Net loss [1] (10,604,886) (10,190,932)
Net loss attributable to non-controlling interest (36,153) (34,173)
Net loss attributable to Intelligent Bio Solutions Inc. (10,568,733) (10,156,759)
Other comprehensive income (loss)    
Foreign currency translation gain (loss) 384,670 (137,118)
Total other comprehensive income (loss) 384,670 (137,118)
Comprehensive loss (10,220,216) (10,328,050)
Comprehensive loss attributable to non-controlling interest (36,153) (34,173)
Comprehensive loss attributable to Intelligent Bio Solutions Inc. $ (10,184,063) $ (10,293,877)
Net loss per share, basic $ (2.00) $ (6.38)
Net loss per share, diluted $ (2.00) $ (6.38)
Weighted average shares outstanding, basic 5,273,643 1,592,746
Weighted average shares outstanding, diluted 5,273,643 1,592,746
[1] Comparative amounts for the prior period have been reclassified to conform to current period presentations.
[2] Comparative amounts for the prior period have been reclassified to conform to current period presentations.
[3] Other segment items included interest income, interest expense, realized currency loss and Fair value gain on revaluation of financial instrument.